Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03675529
Other study ID # H-18020711
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2018
Est. completion date November 24, 2019

Study information

Verified date December 2019
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background and purpose: The purpose of this study is to investigate the effect of one acute exercise bout on tumor hypoxia in patients with localized prostate cancer undergoing radical prostatectomy.

The primary hypothesis is that exercise reduces tumor hypoxia and that the reduction is greater in patients performing one acute high intensity exercise bout compared to no training controls.

The investigators have not been able to identify any prior or current randomized trials investigating exercise and tumor hypoxia, and believe that such research is warranted and would be of great importance. Moreover there is a need for studies including biological measurements to allow a full assessment of the effect of exercise on diverse biomarkers and mechanistic pathways, which may influence cancer survival.

Subjects: Patients with histologically verified prostate adenocarcinoma scheduled for radical prostatectomy at Urologic Department, Rigshospitalet, Copenhagen, Denmark.

Methods: In this randomized controlled pilot study 30 patients with localized prostate cancer undergoing radical prostatectomy will be included and randomized 2:1 to either one single acute High Intensity Interval Training bout or usual care and no training the day prior to radical prostatectomy.

All patients will undergo assessment at inclusion (baseline) and the day prior to surgery.

Assessment includes: anthropometrics; blood pressure; resting hearth rate; hip and waist circumference, ECG, quality of life by self-report questionnaires; fasting blood sample measuring PSA (prostate specific antigen), cholesterol, triglycerides, insulin, c-peptide, HbA1c, glucose and inflammatory markers.

All patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate.

Biological tissue from tumor (primary prostate biopsies) will also be retrieved from the respective local pathological departments and from the perioperative prostate specimen and sent to protocol analyses.


Description:

The purpose of this study is to investigate the effect of one acute exercise bout on tumor hypoxia in patients with localized prostate cancer randomized to one single acute I) High Intensity Interval Training bout compared to (II) usual care and no training prior to radical prostatectomy.

In addition to this the aim is to investigate the effect of one exercise bout on tumor vessel morphology and to investigate the effect of one acute exercise bout on intratumoral immune cell infiltration and to investigate the modulation of tumor-metabolism, -biology and signaling in patients randomized to either one acute High Intensity Interval Training bout compared to usual care and no training, the day prior to surgery.

Moreover this study will explore the acute response in immune cells, hormones and cytokines in blood samples taken before, during and after a single exercise session, and will collect physiological (metabolic profile and metabolic inflammatory markers) and psycho-social (e.g. fatigue, emotional well-being, anxiety) information regarding patients randomized to either one acute High Intensity Interval Training bout compared to usual care and no training, the day prior to surgery.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date November 24, 2019
Est. primary completion date November 24, 2019
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Men with histologically verified localized prostate adenocarcinoma undergoing curative intended radical prostatectomy.

Exclusion Criteria:

- Age: <18 years

- Any other known malignancy requiring active treatment

- Performance status > 1

- Allergy to pimonidazole

- Ongoing treatment with beta blockers

- Physical disabilities precluding physical testing and/or exercise

- Inability to read and understand Danish

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
High Intensity Interval Training bout
Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity. This is followed by 10 minutes at low intensity at approximately 30% of wattmax. Subsequently patients will perform 16 min with 4 cycles with High and Low intensity. HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.

Locations

Country Name City State
Denmark Center for Physical Activity Research, Copenhagen University Hospital Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor hypoxia Quantification of tumor hypoxia will be assessed using pimonidazole staining At prostatectomy
Secondary Intratumoral immune cell infiltration Intratumoral immune cell infiltration will be quantified using histological analyses Primary prostate biopsies and until radical prostatectomy
Secondary Tumor vessel morphology Tumor vessel morphology will be evaluated using histological analyses Primary prostate biopsies and until radical prostatectomy
Secondary Tumor metabolism-, biology and signaling Tumor samples will undergo proteomic analyses in order to uncover potential upregulated biomarkers Primary prostate biopsies and until radical prostatectomy
Secondary Changes in immune cells during an acute exercise bout Changes in immune cells during an acute exercise bout will be measured in blood samples using flowcytometry From start of exercise bout and until 60 minutes post exercise
Secondary Changes in epinephrine concentration Concentration of epinephrine will be measured in blood samples by radioimmunoassay analyses. From start of exercise bout and until 60 minutes post exercise
Secondary Changes in nor-epinephrine concentration Concentration of nor-epinephrine will be measured in blood samples by radioimmunoassay analyses. From start of exercise bout and until 60 minutes post exercise
Secondary Changes in various interleukines Concentration of various interleukines will be measured in blood samples by measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses. From start of exercise bout and until 60 minutes post exercise
Secondary Changes in Tumor Necrosis Factor alpha (TNFa) concentration Concentrations of TNFa will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses. From start of exercise bout and until 60 minutes post exercise
Secondary Changes in Interferon Gamma (IFN?) concentration Concentrations of IFN? will be measured in blood samples by Enzyme-Linked Immunosorbent Assay (ELISA) analyses. From start of exercise bout and until 60 minutes post exercise
Secondary Concentration of C-reactive Protein (CRP) Concentration of CRP will be measured in fasting blood sample by standard laboratory methods. Blood sampling on the day of radical prostatectomy
Secondary Total plasma cholesterol concentration Concentrations of total cholesterol will be measured in fasting blood samples by standard laboratory methods. Blood sampling on the day of radical prostatectomy
Secondary Plasma LDL-Cholesterol concentration Concentrations of LDL- cholesterol will be measured in fasting blood samples by standard laboratory methods. Blood sampling on the day of radical prostatectomy
Secondary Plasma HDL-Cholesterol concentration Concentrations of HDL- cholesterol will be measured in fasting blood samples by standard laboratory methods. Blood sampling on the day of radical prostatectomy
Secondary Plasma triglyceride concentrations Concentrations of triglycerides will be measured in fasting blood samples by standard laboratory methods. Blood sampling on the day of radical prostatectomy
Secondary HbA1C concentration Concentrations of HbA1C will be measured in fasting blood samples by standard laboratory methods. Blood sampling on the day of radical prostatectomy
Secondary Plasma Insulin concentration Concentrations of insulin will be measured in fasting blood samples by standard laboratory methods. Blood sampling on the day of radical prostatectomy
Secondary Plasma Glucose concentration Concentrations of glucose will be measured in fasting blood samples by standard laboratory methods. Blood sampling on the day of radical prostatectomy
Secondary Wattmax-test The participants in the HIIT group will undergo a maximal graded exercise test on a bicycle ergometer for evaluation of cardiovascular function and determination of the maximum watt (wattmax). The test starts with a 3 min warm up at 70 watt (the watts may have to be adjusted to the individual fitness level). Warm up is immediately followed by a 20 watt increase every 1 min until exhaustion. The maximum watt will be calculated. At baseline assessment
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A